- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05166369
Optimisation of Antibiotic Prescription in Acute Noncomplicated Respiratory Tract Infections in Children (OptimAP Study) (OptimAP)
Optimisation of Antibiotic Prescription in Acute Non-complicated Respiratory Tract Infections in Children: a Multicenter Factorial Randomised Controlled Trial Targeting Health Professionals and Parents.
Background: High-volume antibiotic prescribing in primary care is a major driver of antibiotic resistance. Education of physicians and patients can lower prescribing levels, but it frequently relies on highly trained staff. We will assess whether remotely delivered complex interventions including internet-based training for health care provider, and an educational intervention for parents could improve prescribing practices for respiratory tract infections (RTI) in Spain.
Methods: We will develop and evaluate the feasibility of two interventions in a 16-months randomized controlled factorial trial. Primary care (PC) centres will be allocated to one of the following four groups:
- Intervention targeting healthcare providers (paediatricians, nurses and pharmacists): i) Internet based training about communication skills and optimal antibiotic prescribing (including delayed prescribing); ii) bimonthly antibiotic prescription feedback.
- Intervention targeting parents: PC centres allocated to this group will display posters and flyers presenting a mobile app that will include information about respiratory tract infections and optimal use of antibiotics. The app can be used before, during and after the consultation, providing condition specific and patient tailored information.
- Intervention targeting both providers and parents
- No intervention.
During the trial duration we will conduct a process evaluation and a cost-effectiveness analysis. Our primary outcome will be change in the total antibiotic prescription rate. Our secondary outcomes will include: respiratory complications (e.g. pneumonia), antibiotic related adverse effects, repeated consultations, and antibiotic consumption in relation with antibiotic prescribing (delayed antibiotic prescribing). Assuming an average cluster size of 200 RTI consultations per centre, we will need to recruit 222 PC centres.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This project will evaluate the effectiveness of two complex interventions to optimize the use of antibiotics in acute uncomplicated respiratory tract infections (RTI). We will first develop the different components of the interventions and evaluate their feasibility (user testing). We will then conduct a multicenter, randomized, controlled trial to evaluate the effectiveness of the overall intervention and its two main constituents in reducing antibiotic consumption. For this reason we will implement a 2x2 factorial randomized cluster clinical trial based on healthcare practices. They will be randomized to receive the intervention targeted to parents, intervention targeted health care professionals, both interventions, or none of them. We will need to recruit a sample size of 222 primary care centres, allocated in a ratio of 1:1:1:1 to one of the four intervention groups (assuming an average cluster size of 200 RTI consultations per centre). Study setting will be defined as primary care centres in four Autonomous Communities in Spain (Catalonia, Balearic Islands, Navarra and Basque Country) with a total of more than 600 PC centers, 1,200 pediatricians, and more of one million children. Finally, during the trial duration, we will conduct a process evaluation and an economic evaluation with a cost-effectiveness analysis.
The interventions include the main characteristics of successful interventions to reduce antibiotic prescribing identified in a systematic review: engage children, occur prior to an illness episode, employ delayed prescribing, and provide guidance on specific symptoms (Andrews 2012). Furthermore, the factorial design will inform about their relative merits and the process evaluation about the potential effect of the individual components.
The research team in in Barcelona (Spain) will coordinate the overall running of the project. A research coordinator in Barcelona will run the day to day of the project from day one under the supervision of the principal investigator. The research teams in four different Spanish Autonomous Communities will contribute to all the stages (intervention development, clinical trial, and economic and process evaluation). Patient representatives will be involved in the project as co-investigators and members of the Steering Committee. Throughout the project groups of parents at each of the regions will be providing feedback.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08041
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
-
Pamplona, Spain
- Servicio Navarro de Salud - Osasunbidea
-
-
Gipuzkoa
-
Pasaia, Gipuzkoa, Spain, 20110
- Osakidetza - Ambulatorio de Pasai San Pedro
-
-
Illes Balears
-
Palma De Mallorca, Illes Balears, Spain, 07120
- Institut d'Investigació de les Illes Balears (IdISBa)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthcare professionals who care for children in primary care centres and community pharmacists of reference in four Autonomous Communities of Spain (Catalonia, Balearic Islands, Navarra and Basque Country).
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention targeted to healthcare providers (paediatricians, nurses and pharmacists) (ITHP)
Professionals in the PC centres allocated to this group will receive a complex intervention, delivered remotely, which will include the following components: i) Web based training that will include: communication skills training and optimal management of acute non-complicated RTI, including a specific training on delayed antibiotic prescription. ii) By-monthly feedback about the rate of antibiotic prescription and consumption for RTI, center level and individual pediatrician level (information automatically gathered from electronic health records). |
This intervention consists of a course on communication skills for healthcare professionals. It will be done remotely via the internet and will include: communication skills training and optimal management of acute non-complicated RTI and delayed antibiotic prescription. Training modules will be delivered via a specific website password protected. Healthcare professionals will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI. |
|
Experimental: Intervention targeted to parents (ITP)
PC centres allocated to this group will display posters and flyers to inform parents and/or caregivers about a mobile app.
It will provide detailed information about respiratory tract infections and optimal use of antibiotics.
The app will include information that will be of use before the consultation, but it will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making.
Importantly, the app will allow tailoring the guidance provided according to the type of infection or number of days with symptoms.
The app will be accessible through an app store or directly using a QR (quick response) code to facilitate uptake.
Professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI, at center level and individual pediatrician level (information automatically gathered from electronic health records).
|
This intervention involves the use of a mobile phone application by parents and caregivers. The mobile app will provide information, education and interactive tools about acute noncomplicated respiratory tract infections. PC centres allocated to this group will display posters and flyers to inform parents and caregivers about the mobile app. Healthcare staff will also promote the use of this app by parents and caregivers. The app information will be useful before the consultation, and will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making. Importantly, the app will allow tailoring the guidance provided according to the type of infection or the number of days with symptoms. Healthcare professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI. |
|
Experimental: Intervention targeted to patients and/or patient´s parents and to the healthcare providers (ITHP*P)
Centres allocated to this group will receive the two interventions described above (intervention targeted to parents plus intervention targeted to providers).
|
This intervention consists of a course on communication skills for healthcare professionals. It will be done remotely via the internet and will include: communication skills training and optimal management of acute non-complicated RTI and delayed antibiotic prescription. Training modules will be delivered via a specific website password protected. Healthcare professionals will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI. This intervention involves the use of a mobile phone application by parents and caregivers. The mobile app will provide information, education and interactive tools about acute noncomplicated respiratory tract infections. PC centres allocated to this group will display posters and flyers to inform parents and caregivers about the mobile app. Healthcare staff will also promote the use of this app by parents and caregivers. The app information will be useful before the consultation, and will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making. Importantly, the app will allow tailoring the guidance provided according to the type of infection or the number of days with symptoms. Healthcare professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI. |
|
No Intervention: Control group
The centers allocated to this arm of the study will continue with their usual care.
To avoid a potential Hawthorne effect (observer effect) these centers will not be informed about their participation as controls.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total antibiotic prescription rate
Time Frame: Three months (from 1st January 2022 to 31st March 2022)
|
Total antibiotic prescription rate for patients between 0 and 14 years old (children).
|
Three months (from 1st January 2022 to 31st March 2022)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
RTI complication rate
Time Frame: Three months (from 1st January 2022 to 31st March 2022)
|
Rate of clinical complications of respiratory tract infection (e.g.
pneumonia, otitis media, sinusitis).
|
Three months (from 1st January 2022 to 31st March 2022)
|
|
Hospital admission rate due to RTI
Time Frame: Three months (from 1st January 2022 to 31st March 2022)
|
Hospital admission rate due to a RTI or a related complication at 30 days after index RTI consultation.
|
Three months (from 1st January 2022 to 31st March 2022)
|
|
RTI Re-consultation rate
Time Frame: Three months (from 1st January 2022 to 31st March 2022)
|
RTI re-consultations rates at 7, 14, or 31 days after index RTI consultation.
|
Three months (from 1st January 2022 to 31st March 2022)
|
|
Antibiotic-related adverse events rate
Time Frame: Three months (from 1st January 2022 to 31st March 2022)
|
Antibiotic-related adverse events rate (as registered in clinical records).
|
Three months (from 1st January 2022 to 31st March 2022)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Pablo Alonso Coello, PhD, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Publications and helpful links
General Publications
- Andrews T, Thompson M, Buckley DI, Heneghan C, Deyo R, Redmond N, Lucas PJ, Blair PS, Hay AD. Interventions to influence consulting and antibiotic use for acute respiratory tract infections in children: a systematic review and meta-analysis. PLoS One. 2012;7(1):e30334. doi: 10.1371/journal.pone.0030334. Epub 2012 Jan 27.
- Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010 May 18;340:c2096. doi: 10.1136/bmj.c2096.
- Ranji SR, Steinman MA, Shojania KG, Gonzales R. Interventions to reduce unnecessary antibiotic prescribing: a systematic review and quantitative analysis. Med Care. 2008 Aug;46(8):847-62. doi: 10.1097/MLR.0b013e318178eabd.
- Little P, Stuart B, Francis N, Douglas E, Tonkin-Crine S, Anthierens S, Cals JW, Melbye H, Santer M, Moore M, Coenen S, Butler C, Hood K, Kelly M, Godycki-Cwirko M, Mierzecki A, Torres A, Llor C, Davies M, Mullee M, O'Reilly G, van der Velden A, Geraghty AW, Goossens H, Verheij T, Yardley L; GRACE consortium. Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial. Lancet. 2013 Oct 5;382(9899):1175-82. doi: 10.1016/S0140-6736(13)60994-0. Epub 2013 Jul 31.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19/019-P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Tract Infections
-
Hospices Civils de LyonNot yet recruitingCOVID-19 Infections | Respiratory Infections, AcuteFrance
-
Vastra Gotaland RegionGöteborg University; Sahlgrenska University HospitalNot yet recruitingPneumonia | Respiratory Failure | Respiratory Insufficiency | ARDS (Acute Respiratory Distress Syndrome)Sweden
-
Qingyuan ZhanThe First Affiliated Hospital of Guangzhou Medical University; Wuhan Metware...Not yet recruitingAcute Respiratory Failure | Community-Acquired Pneumonia
-
Washington University School of MedicineNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Wits Health Consortium (Pty) LtdFred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; National Institute... and other collaboratorsCompletedSARS (Severe Acute Respiratory Syndrome)South Africa
-
Hôpital Universitaire SahloulCompleted
-
Massachusetts General HospitalXijing Hospital; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Niguarda...CompletedCoronavirus | SARS (Severe Acute Respiratory Syndrome)United States, Sweden
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsCompleted
-
University of SaskatchewanGovernment of Canada; Government of SaskatchewanWithdrawnSevere Acute Respiratory Syndrome Coronavirus 2
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsCompletedSevere Acute Respiratory Syndrome Coronavirus 2Canada
Clinical Trials on Communication skills training
-
University Hospital, Basel, SwitzerlandUniversity of Basel; Max Planck Institute for Human DevelopmentCompletedInformation Structuring Skills | Empathy SkillsSwitzerland
-
St. Jude Children's Research HospitalRecruitingCommunicationUnited States
-
Jules Bordet InstituteUniversité Catholique de Louvain; Université Libre de Bruxelles; Université de... and other collaboratorsUnknownPhysician Patient RelationshipBelgium
-
Montefiore Medical CenterNational Institute on Minority Health and Health Disparities (NIMHD); Dartmouth... and other collaboratorsCompletedCritical Illness | Terminal IllnessUnited States
-
US Department of Veterans AffairsCompleted
-
University of St AndrewsNHS Lothian; Breast Cancer NowUnknownBreast CancerUnited Kingdom
-
Tulane University School of MedicineRobert Wood Johnson FoundationCompletedCervical Cancer | Breast Cancer | Colorectal CancerUnited States
-
Johns Hopkins Bloomberg School of Public HealthNational Institute of Mental Health (NIMH)CompletedMental Disorders Diagnosed in ChildhoodUnited States
-
Oslo University HospitalUniversity Hospital, Akershus; Lovisenberg Diaconal University CollegeEnrolling by invitationCritical Illness | Communication | Intensive Care Unit SyndromeNorway
-
Universitätsklinikum Hamburg-EppendorfActive, not recruiting